Sense Biodetection
Instrument-free, rapid, point-of-care molecular diagnostic tests.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 210.1x EV/Revenue -22.4x EV/EBITDA | round | |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| GBP | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (59 %) | (99 %) | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (25 %) | (939 %) | (256913 %) | - |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (37 %) | (948 %) | (251707 %) | (254012 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 94 % | 751 % | 96972 % | - |
Source: Company filings or news article
Related Content
Sense Biodetection, founded in 2014 by Harry and Ralph Lamble, was a global molecular diagnostics company that developed instrument-free, point-of-care tests. In February 2023, the company was acquired by Sherlock Biosciences for undisclosed terms. The acquisition was aimed at accelerating Sherlock's market strategy by integrating Sense's Veros™ platform and manufacturing capabilities.
The company was headquartered in Abingdon, United Kingdom, with additional operations in Cambridge, UK, and Milford, Massachusetts, USA. Sense focused on developing disposable molecular diagnostic tests that provided laboratory-quality results without the need for a reader or external power. Its proprietary Veros™ product platform utilized rapid molecular amplification technology to detect various diseases. The first product launched on this platform was the Veros™ COVID-19 test, which received a CE Mark in March 2022, allowing it to be sold in the European Union. This test could deliver PCR-quality results from a nasal swab in under 15 minutes.
The company's business model centered on providing accessible and affordable diagnostic solutions to improve patient outcomes and lower healthcare costs by enabling testing in various settings beyond traditional laboratories. Sense had secured a total of $79.2 million in funding over six rounds from investors including Koch Disruptive Technologies, Cambridge Innovation Capital, and Earlybird Health. The acquisition by Sherlock Biosciences combines Sense's hardware and chemistry with Sherlock's CRISPR-based technologies to advance the development of handheld, highly accurate tests for a range of health issues, including respiratory and sexual health.
Keywords: molecular diagnostics, point-of-care testing, instrument-free diagnostics, rapid diagnostic tests, Veros platform, COVID-19 test, healthcare technology, medical devices, disposable diagnostics, nucleic acid amplification, decentralized testing, CE Mark, infectious disease testing, Sherlock Biosciences acquisition, diagnostic technology, biotechnology